How much funding has NuCana raised?

NuCana has raised $67.3M in total funding, most recently a Extension Round.

Who are NuCana's investors?

NuCana's investors include Sofinnova Partners.

Where is NuCana headquartered?

NuCana is headquartered in Edinburgh, United Kingdom.

What industry is NuCana in?

NuCana operates in Biotech, Healthcare.

NuCana

Edinburgh, United Kingdom · Founded 2008 · $67.3M raised

Biotech

Healthcare

Headquarters: Edinburgh
Employees: 11–50
Founded: 2008
Business Model: B2B

Website: nucana.com
Total Funding: $67.3M
Last Round: $10.3M Extension RoundJun 2025
Rounds: 2

About

NuCana is a Nasdaq-listed, clinical-stage biopharmaceutical company headquartered in Edinburgh, Scotland, focused on significantly improving treatment outcomes for patients with cancer. Founded in 2008 by CEO Hugh Griffith, the company applies its proprietary ProTide phosphoramidate technology to transform established nucleoside analogs into more effective and safer anti-cancer medicines designed to overcome key cancer resistance mechanisms. NuCana's pipeline includes candidates targeting colorectal, pancreatic, and other cancers, with the ProTide platform enabling much higher concentrations of active anti-cancer metabolites within tumor cells compared to conventional chemotherapy. The company also maintains a U.S. office in Newton, Massachusetts.

Summary

NuCana is a Biotech company based in Edinburgh, United Kingdom, founded in 2008. It has raised $67.3M in total across 2 rounds, most recently a $10.3M Extension Round round in Jun 2025. Investors include Sofinnova Partners.